AcuamarkDx key facts
as of Oct 2026- Developer of a cancer screening blood technology designed to detect cancer markers at early stages.
- AcuamarkDx is valued at approximately $85.0M as of Oct 2026 (last reported valuation).
- It has raised $25.0M; the latest was Later Stage VC ($4.9M) in Apr 2026.
- Notable investors include 1955 Capital, Bruker, Cornell University, HBS Alumni Angels of Greater New York, XLerateHealth.
- Status: Privately Held (backing).
AcuamarkDx's last reported valuation, Jun 2024. Nothing priced has surfaced since.
- ·Watch AcuamarkDx: the Monday email on marks, rounds and moves
AcuamarkDx funding rounds
No funding rounds for AcuamarkDx are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
AcuamarkDx valuation
AcuamarkDx's last reported valuation was $85 million in Jun 2024. No priced round, secondary trade or fund mark has surfaced since.
AcuamarkDx investors
5 investors are on record for AcuamarkDx, including 1955 Capital, Bruker, Cornell University and HBS Alumni Angels of Greater New York.
About AcuamarkDx
Developer of a cancer screening blood technology designed to detect cancer markers at early stages. The company's technology integrates a suite of novel, multiplexed assays that test for several levels of molecular change through frequent, recurrent, sequential monitoring and screening, enabling doctors to get a scalable and economical blood-based screening result for early detection of cancer, heart disease, thyroid function, and diabetes.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2012
- Employees
- 8
- Website
- acuamarkdx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.